Core F: Biomarker Core

核心 F：生物标志物核心

• 批准号: 10652573
• 负责人: LEE E. GOLDSTEIN
• 金额: $ 33.13万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10652573
• 关键词: Address; Ally; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; Amyloid; Amyloid beta-Protein; Atrophic; Biological Markers; Biometry; Blood; Boston; Brain imaging; Cells; Cerebrum; Clinical; Clinical Research; Collaborations; Communities; Data; Dementia; Detection; Development; Diagnosis; Differential Diagnosis; Disease; Doctor of Medicine; Doctor of Philosophy; Early Diagnosis; Early Intervention; Early treatment; Education; Emerging Technologies; Faculty; Generations; Goals; Hippocampus; Human; Image; Imaging Techniques; Institution; International; Ligand Binding; Light; Liquid substance; MRI Scans; Magnetic Resonance Imaging; Measures; Mentorship; Mission; Molecular Profiling; Monitor; National Institute on Alcohol Abuse and Alcoholism; Nerve Degeneration; Neurobehavioral Manifestations; Neurodegenerative Disorders; Neurons; Participant; Peptides; Plasma; Positron-Emission Tomography; Postdoctoral Fellow; Process; Protocols documentation; Qualifying; Research; Research Personnel; Resources; Risk Assessment; Scientist; Serum; Specimen; Staging; Targeted Research; Testing; Therapeutic; Thick; Training; United States National Institutes of Health; Universities; Update; Ventricular; accurate diagnosis; biomarker development; biomarker discovery; biomarker validation; brain volume; chronic traumatic encephalopathy; clinical development; cohort; cost effective; data management; data sharing; early-career faculty; education research; entorhinal cortex; exosome; experience; genetic profiling; improved; insight; interest; member; multimodality; neurofilament; neuroimaging; neuroimaging marker; neuropathology; next generation; normal aging; novel; personalized medicine; pre-clinical; prevent; research clinical testing; response; statistics; tau Proteins; tau-1; white matter

Biomarkers provide important information for early detection, differential diagnosis, and disease monitoring of Alzheimer’s disease (AD) and AD-related dementias (ADRDs), including chronic traumatic encephalopathy (CTE). The newly established Biomarker Core of the Boston University Alzheimer’s Disease Research Center (BU ADRC) will be led by three clinician-scientists with experience in biomarker development and validation: Lee Goldstein, M.D., Ph.D. and Wendy Qiu, M.D., Ph.D., who will serve as co-leaders, and Ronald Killiany, Ph.D., who will lead the neuroimaging component. The Biomarker Core will leverage their expertise and existing institutional resources to focus on fluid biospecimen and neuroimaging biomarkers relevant to Alzheimer’s disease (AD) and related dementias (ADRD), including chronic traumatic encephalopathy (CTE). The goal of the Biomarker Core is to collaborate with other cores and centralize biomarker initiatives to support the BU ADRC mission to improve early and accurate diagnosis, differentiation, and monitoring of AD and ADRDs, including CTE. The new Biomarker Core will bank, distribute, and analyze fluid biospecimens and neuroimaging data for shared use by investigators within and outside the BU ADRC and allied national consortia. We will focus on established biofluid and neuroimaging biomarkers (Amyloid-Tau-Neurodegeneration A/T/N NIA-AA Research Framework) with the goal of identifying differences between AD and ADRDs. The Core will also conduct discovery-based development of novel emerging biofluid and neuroimaging biomarkers to enable earlier and more accurate detection, differential diagnosis, staging, and tracking of AD and ADRDs across the disease spectrum. Four Specific Aims are proposed. Aim 1: Process, bank, and distribute fluid biospecimens and neuroimaging data. Aim 2: Measure and analyze established biomarkers (A/T/N NIA-AA Research Framework). Aim 3: Conduct discovery and development of emerging biomarkers, including analysis of blood-derived exosomes and multimodal computational strategies for neuroimaging data. Aim 4: Train next-generation AD biomarker and neuroimaging research leaders. We anticipate that the new Biomarker Core will strengthen BU ADRC research, promote sharing of fluid and neuroimaging biomarker resources, harmonize with efforts to advance national AD/ADRD initiatives, and provide new new insights and biometrics for personalized medicine approaches to diagnose, treat, and prevent AD and ADRD.

生物标志物为早期检测，鉴别诊断和疾病监测提供了重要信息 阿尔茨海默氏病（AD）和与AD相关的痴呆症（ADRDS），包括慢性创伤性脑病 （CTE）。波士顿大学阿尔茨海默氏病研究中心的新成立的生物标志物核心 （BU ADRC）将由三位具有生物标志物开发和验证经验的临床科学家领导：Lee 医学博士Goldstein博士以及将担任联合领导者的医学博士Wendy Qiu和Ronald Killiany博士 谁将领导神经影像成分。生物标志物核心将利用其专业知识和现有 与阿尔茨海默氏症相关的生物标志物和神经影像学的机构资源 疾病（AD）和相关痴呆症（ADRD），包括慢性创伤性脑病（CTE）。目标的目标 生物标志物核心是与其他核心合作，并集中生物标志物计划以支持BU ADRC 要改善对AD和ADRD的早期和准确诊断，差异化和监视的使命，包括 CTE。新的生物标志物核心将库存，分发和分析流体生物测量和神经成像数据 BU ADRC和联盟国家财团内外的调查人员共同使用。我们将重点关注 已建立的生物流体和神经影像学生物标志物（淀粉样蛋白-tau-neurodegeneration A/T/N NIA-AA研究 框架），目的是确定AD和ADRD之间的差异。核心也将进行 基于发现的新型生物流体和神经影像制定生物标志物的基于发现的发展，以使早期和 更准确的检测，鉴别诊断，分期以及对疾病的AD和ADRD的跟踪 光谱。提出了四个具体目标。目标1：过程，银行和分发液体生物测量和 神经影像数据。目标2：测量和分析已建立的生物标志物（A/T/N NIA-AA研究框架）。 目标3：进行新兴生物标志物的发现和开发，包括对血液的分析 神经影像数据的外泌体和多模式计算策略。目标4：火车下一代广告 生物标志物和神经影像学领导者。我们预计新的生物标志物核心将加强BU ADRC研究，促进流体和神经影像学生物标志物资源的共享，并努力协调 推进国家广告/ADRD计划，并为个性化医学提供新的新见解和生物识别技术 诊断，治疗和预防AD和ADRD的方法。